CIRM Funded Clinical Trials

Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients


Mehrdad Abedi
Disease Area: 
HIV-related Lymphoma
Investigator:
CIRM Grant:
Award Value:
$8,521,441
Trial Stage: 
Phase 1/2
Trial Status: 
Suspended
Targeted Enrollment:
18
ClinicalTrials.gov ID:
Details: 

Lentiviral vector encodes a triple combination of HIV-resistance genes and a pre-selective marker. Vector transduced CD34+ cells will safely engraft, divide and differentiate in vivo into mature myeloid and lymphoid cells.

Design: 

Open label, single arm study.

Goal: 

Safety. Efficacy - immune reconstitution, viral load and HIV status.

Status: 

This study has suspended participant recruitment.